Decreased natural killer activity in thalassemia major: a possible consequence of iron overload.
We have investigated the natural killer (NK) activity of both fractionated (Percoll density gradient) and unfractionated mononuclear cells from patients with beta-thalassemia major who are iron overloaded as a consequence of chronic transfusion therapy. These patients were found to have significantly decreased NK activity against K562 targets at all effector:target ratios tested (p less than 0.001). Both splenectomized and nonsplenectomized patients had normal proportions of Leu-11b-staining (NK) cells. Since they had normal to elevated absolute white cell and lymphocyte counts, a change in the absolute number of NK cells could not account for the decreased killing. We also found that the decrease in NK activity was transfusion related (r = -0.603, p less than 0.005). To determine whether or not this decrease in NK activity could be related to iron overload, we preincubated patient effector cells with desferrioxamine (DFO) or 2,3-dihydroxybenzoic acid (DHB) for 6 hr before addition of K562 targets. Both of these iron-chelating agents consistently increased the NK activity of cells from thalassemia patients. DHB had the greater effect, being able to increase patient NK activity to virtually normal levels. On the other hand, preincubation of cells from normal controls with DHB caused only a slight increase in NK activity, while similar treatment with DFO had little or no effect. When target cells were preincubated with the chelating agents before addition of either normal or patient effector cells, no change in cytotoxicity was seen, demonstrating that the chelating agents act at the effector cell level. Furthermore, if the chelating agents were saturated with iron prior to preincubation with the effectors, no increase in the cytotoxicity of thalassemic NK cells was observed. These results indicate that thalassemia patients have a reversible, transfusion-related decrease in NK function which may arise as a consequence of iron overload.
D002469:Cell Separation; D002499:Centrifugation, Density Gradient; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000276:immunology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007501:Iron / Q000097:blood*; D007502:Iron Chelating Agents / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology*; D011205:Povidone; D012822:Silicon Dioxide; D013789:Thalassemia / Q000276:immunology* / Q000628:therapy; D065227:Transfusion Reaction
D007166:Immunosuppressive Agents; D007502:Iron Chelating Agents; C016039:Percoll; D012822:Silicon Dioxide; D007501:Iron; D011205:Povidone